Detailed data are expected later, but partners Biontech SE and Duality Biologics Co. Ltd. are celebrating a phase III interim ...

About two years since its founding, new company Radiance Biopharma Inc. signed a deal in which it could pay up to $1.165 ...

Sometimes little things can create big problems, which seems to be the case with the recall of the power unit used with the ...

IMU Biosciences Ltd. is working to transform society’s understanding of the immune system. The company’s platform maps the ...

Edwards Lifesciences Corp. fully acquired Vectorious Medical Technologies Ltd. for $497 million, following a series of investments in the heart failure technology company over the last five years.

Metabolic dysfunction-associated steatotic liver disease (MASLD) now affects over a third of adults worldwide. Its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), is a ...

Braveheart Bio Inc. is paying $65 million up front to license Jiangsu Hengrui Pharmaceuticals Co. Ltd.’s oral hypertrophic ...

Axovia Therapeutics Inc. has been awarded a new $1.0 million grant by the nonprofit organization A Race Against Blindness to ...

A recent paper in the Journal of Clinical Medicine quantified some of the potential bodily ravages ahead for patients with ...

If a cancer patient has bone metastases, they will frequently have anemia as well. Given that the bone marrow is the site of blood cell formation, this observation is perhaps not unexpected. But its ...

Padarn Therapeutics Inc. has described CDK2/cyclin A2 and CDK1/cyclin A2 inhibitors reported to be useful for the treatment of cancer.

Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, ...